What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A single dose of 18F-RAD101 with a maximum of 370 MBq (10 mCi) administered as a slow IV bolus injection over a maximum of 30 seconds, followed by a saline flush.”In the company’s words, NCT06777433 on ClinicalTrials.gov
- Tested for
- Brain Metastases From Solid Tumors
- Main trialPhase 2
- “This is an open-label, single dose, single arm, multicenter Phase 2b study to establish the imaging performance of RAD101 PET in participants who are ≥ 18 years of age and with suspected recurrent brain metastases from solid tumors. The study consists of a 4-week Screening Period, a 3-day Imaging and Safety Follow-Up Period, and a Data Collection Period of up to 6 months. Participant eligibility will be determined during the Screening Period and eligible participants will be enrolled in the study. On Day 1, the enrolled participants will receive a single dose of the investigational medicinal…”In the company’s words, NCT06777433 on ClinicalTrials.gov
Other drugs for Brain Metastases From Solid Tumors
- Floretyrosine FTelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- HBI-8000HUYABIO International, LLC. · Phase 3
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
- Allogeneic genetically modified gamma-delta T cellsIn8bio Inc. · Phase 1/2
- Autologous genetically modified gamma-delta T cellsIn8bio Inc. · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 23 Apr 2026 | Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026